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baculovirus expression vector under the control of the polyhedrin promoter. The resulting recombinants expressed the appropriate authentic VP4 rotavirus outer capsid protein.
Guinea pigs immunized with these VP4 proteins developed antibodies that neutralized infectivity of the rotavirus from which the immunizing VP4 was derived. These antisera were then used in neutralization tests to define the extent and distribution of VP4 antigenic polymorphism among human rotaviruses. Three distinct serotypes and one subtype of the VP4 outer capsid protein were identified among 17 human rotavirus strains that had previously been assigned to five distinct VP7 serotypes. For the most part, VP4 serotype segregated independently of VP7 serotype. Ten strains of human rotavirus that were associated with symptomatic infection and that exhibited VP7 serotype 1, 3, 4, or 9 specificity, each possessed a VP4 of the same serotype and subtype, designated VP4 serotype 1A. Both symptomatic human rotavirus strains with VP7 serotype 2 specificity were related by neutralization to the VP4 serotype 1A strains and were classified as a subtype of VP4 serotype 1-i.e., serotype lB-since viruses of serotype 1A appeared to be prime strains. Four human rotavirus strains that were recovered from healthy infants in newborn nurseries in which virus transmission persisted over a long interval, belonged to VP7 serotype 1, 2, 3, or 4, but each strain possessed the same VP4 antigenic specificity that was designated VP4 serotype 2. Finally, a single strain of symptomatic human rotavirus of VP7 serotype 1 specificity possessed a unique VP4 that was provisionally classified as VP4 serotype 3 but this remains to be confirmed because neutralization tests were performed in only one direction. Among the 10 rotavirus strains whose VP4 gene was previously sequenced, there was complete concordance between assignment of VP4 serotype by neutralization and classification according to VP4 amino acid homology. Thus, rotaviruses that exhibited a VP4 amino acid homology of 89% or greater belonged to the same VP4 serotype and subtype as determined by neutralization. Finally, evidence was obtained that the serotype-specific domain is located on the VP8 subunit of VP4.
Rotaviruses are ubiquitous agents that cause diarrheal disease in the young of not only humans but also many animal species (1) . Several candidate vaccines against human rotavirus (HRV) disease are currently being evaluated with special emphasis on the VP7 outer capsid protein, which is a major protective antigen (2, 3) . At least six different serotypes have been established among HRVs based on the antigenic specificity of VP7 (1) . The outer capsid protein, VP4, is also a major protective antigen, but relatively little is known about the antigenic relationships of the VP4 of various HRVs. It has been demonstrated by sequence analysis that at least four alleles of the VP4 gene are present among HRVs (4) (5) (6) (7) . One allele of VP4 is present on symptomatic strains that are classified by means of VP7 as serotype 1 (strains KU and Wa), serotype 3 (strain P), or serotype 4 (strain VA70). These rotavirus strains, designated as VP4 genetic group 1, possess a highly conserved VP4 protein that exhibits 93-97% amino acid identity. A second allele of VP4 is present in HRVs belonging to VP7 serotype 2 (strains DS-1 and RV-5) that exhibit 98% VP4 amino acid identity. These strains, designated as VP4 genetic group 2, were also recovered from symptomatic infections. Moreover (4) . Viral mRNA was synthesized in vitro by the endogenous transcriptase in viral cores and was freed of double-stranded RNA by precipitation with 2 M lithium chloride (4) . The construction of VP4 cDNAs followed the method described Transfection and the selection of the recombinants were performed as described (9) . The corresponding baculovirus VP4 recombinants were designated as KU-G4, DS-1-G4, and 1076-G4. Guinea pigs were immunized with a lysate of KU, DS-1, or 1076 baculovirus recombinant-infected Sf9 cells as described (9) . Following immunization, serum samples were tested for antibodies to VP4 by immunoprecipitation and plaque neutralization assays (10, 11) .
Construction, in Vitro Transcription, and Translation of the VP8 and VP5 Subunits of VP4 of Rotavirus Strain KU, DS-1, or 1076. The sequences for the VP8 and VP5 subunits of VP4 of HRV strain KU, DS-1, or 1076 were amplified by the polymerase chain reaction (12) (see above) were used together with oligonucleotide 5'-CACGGATC-CACCATGGTTAATGAAGATATTA-3', which is complementary to the completely conserved sequence at positions 756-771 in the KU, DS-1, or 1076 VP4 gene. The latter primer was designed to substitute alanine for threonine at the amino terminus of VP5 and replace glutamine for methionine at the second position in order to achieve a sequence highly favorable for initiation of translation. This primer also created a BamHI flanking site. After amplification, VP5 cDNA was digested with BamHI, whereas VP8 cDNA was digested with BamHI/Bgl II. The resulting products were chromatographed on a NACS column (BRL) and cloned into pTZ18R. For in vitro transcription ofthe VPS and VP8 subunits of KU, DS-1, or 1076, plasmids were selected for the correct T7 promoter orientation by restriction enzyme mapping and sequencing. Transcripts of VP5 and VP8 were produced using a Riboprobe system kit (Promega) following the manufacturers' specifications. In vitro translation was performed using rabbit reticulocyte lysate treated with nuclease (Promega). One microgram of RNA and 1 mCi of [35S]_ methionine per ml (>800 Ci/mmol; 1 Ci = 37 GBq) were added to 50 ,ul of reaction mixture. After incubation at 370C for 1 hr, the samples were immunoprecipitated by guinea pig hyperimmune antiserum to human strain Wa (possessing the same VP4 serotype as KU), DS-1, or M37 (possessing the same VP4 serotype as 1076) or by guinea pig antiserum produced to each of the baculovirus recombinant-expressed VP4 proteins. The translated VP4 subunit proteins were also used to assay for VP5-and VP8-specific antibodies in postinfection serum of a gnotobiotic piglet (61-5) infected with human strain Wa rotavirus from which the VP4 gene insert was derived (Fig.  1) . The identity of the expressed VP4 proteins was confirmed in this instance by immunoprecipitation with the appropriate guinea pig antiserum to purified virus of rotavirus strain Wa (that has a VP4 highly homologous in amino acid sequence to KU VP4), DS-1, or M37 (that has a VP4 highly homologous in amino acid sequence to 1076 VP4).
The baculovirus recombinant-expressed rotavirus VP4 protein of KU, DS-1, or 1076 was immunogenic because immunization of guinea pigs induced the development of antibodies that immunoprecipitated an 85-kDa protein from a lysate of strain KU, DS-1, or 1076 infected MA104 cells, respectively (Fig. 2) . The gel mobility of these proteins was similar to that of authentic VP4 immunoprecipitated by the appropriate virus antiserum.
Antigenic Relationships Among the Baculovirus Recombinant-Expressed VP4 Proteins of HRVs Assayed by Neutralzation. Antigenic relationships of the baculovirus recombinantexpressed VP4s were studied by cross-neutralization tests performed with guinea pig antiserum to the VP4 of KU, DS-1, or 1076. Previously, each of these VP4 proteins was shown to belong to a different VP4 genetic group as defined by VP4 amino acid homology (4, 5) . Analysis of 17 HRVs revealed three nonoverlapping patterns of neutralization suggesting that there are at least three distinct HRV VP4 serotypes (1, 2, and 3) and one subtype (1B) ( Table 1 ). Antiserum to the KU VP4 neutralized 10 HRVs to high titer (1:1920 to 21: 2560). These rotaviruses were (i) recovered from patients with diarrheal disease and (ii) represented four distinct VP7 serotypes, 1, 3, 4, and 9. The KU VP4 antiserum also neutralized two symptomatic strains of VP7 serotype 2 to a high titer that was -2-fold lower than that observed for the aforementioned group of viruses. The four asymptomatic strains were neutralized to a significantly lower titer by the KU VP4 antiserum (i.e., 8-fold lower than the homologous titer), whereas the single strain (K8) of the remaining group was not neutralized at all. Antiserum to DS-1 VP4 neutralized the two viruses of the second genetic group (the symptomatic DS-1 and S2 strains) to highest titer, whereas neutralization of the first genetic group was 4-to 8-fold less efficient. The DS-1 VP4 antiserum failed to neutralize viruses of the third or fourth genetic group. Finally, the four asymptomatic neonatal strains formed a homogeneous group that was neutralized to high titer by antiserum against VP4 of one of its member strains (1076). This antiserum neutralized the first and second genetic groups of strains with 16-to 32-fold lower efficiency, whereas the single strain of genetic group 4 (K8) was not neutralized at all.
The VP4 of the fourth genetic group, represented by strain K8, appeared to be the most distinct, differing from the first three VP4 genetic groups by its failure to be neutralized by antisera to any of the baculovirus recombinant-expressed VP4s. The third genetic group was also clearly distinct from each of the other groups as indicated by an 8-to 32-fold reduction in heterologous neutralization titer in reciprocal assays. Finally, the first and second groups appeared to be the most closely related of the four genetic groups because reciprocal differences in neutralizing antibody titer between groups 1 and 2 were only 2-fold in one direction and 4-to 8-fold in the other direction. In cross-neutralization tests involving groups 1 and 2, the group 1 antiserum (KU) exhibited more cross-reactivity than the group 2 antiserum (DS-1). Since the KU strain appeared to be the prime strain, the group 2 viruses were considered to be a subtype of VP4 serotype 1.
Distribution of Serotype-Specific and Cross-Reactive Antigenic Sites on VP4. Previous studies had provided evidence that amino acid homology among distantly related rotavirus VP4 proteins was greater in the VP5 cleavage subunit of VP4 than in the VP8 cleavage subunit (5). Furthermore, neutralizing monoclonal antibodies directed at a site on VP5 exhibited considerable cross-reactivity for heterologous rotaviruses, whereas neutralizing monoclonal antibodies directed at a site on VP8 were observed to be more specific (14, 15) . Because of these findings, the VP5 and VP8 cleavage subunits of VP4 were studied to determine if the overall antigenic specificity of these subunits followed the patterns observed for amino acid sequence homology and reactivity with homologous or heterologous monoclonal antibodies.
VP8 or VP5 was transcribed in vitro from the appropriate cloned cDNA and translated in a rabbit reticulocyte lysate. The translated VP8 or VP5 was then immunoprecipitated with (i) guinea pig hyperimmune antiserum to purified virions of strain Wa (VP4 serotype 1A), DS-1 (VP4 serotype 1B), or M37 (VP4 serotype 2); (ii) guinea pig antiserum to baculovirus recombinant-expressed VP4 of KU (VP4 serotype 1A), DS-1 (VP4 serotype 1B), or 1076 (VP4 serotype 2); or (iii) serum obtained after infection of a gnotobiotic calf or piglet K8 <80 <80 <80 PRN, plaque reduction neutralization. *The three VP4 serotypes and the one VP4 subtype correspond to four genetic groups that were defined previously by the degree of VP4 amino acid sequence homology. VP4 genetic groups 1, 2, 3, and 4 correspond to VP4 serotypes 1A, 1B, 2, and 3, respectively (4-7).
with strain Wa, DS-1, or M37. In tests performed with the VP4 subunits of KU (VP4 serotype 1A), DS-1 (VP4 serotype 1B), or 1076 (VP4 serotype 2), VP5 was immunoprecipitated by each homotypic and heterotypic antiserum (Fig. 3) . In contrast, the VP8 of each virus reacted in a more specific manner. For example, the VP8 of strain 1076 was precipitated only with homotypic antiserum. However, M37 hyperimmune antiserum did precipitate the VP8 of strain DS-1, but this heterotypic reaction was significantly less than the homotypic reaction (Fig. 3A) . Cross-immunoprecipitation of the VP8 subunits of KU and DS-1 with antisera to purified virus (Fig. 3A) or sera from an infected piglet or calf (Fig. 3C) indicated that KU had a predominantly one-way relationship with DS-1. The exception was the greater immunoprecipitation of KU VP8 by antiserum to baculovirus recombinantexpressed DS-1 VP4 (Fig. 3B) .
The overall pattern that emerges from this analysis of the VP4 subunits is that antigenic determinants shared among serotype 2 VP4 and serotype 1A and 1B VP4s are located primarily on VP5. In addition, the VP8 subunits of serotype 1A VP4 and serotype 1B VP4 share another set of antigenic determinants that may be responsible for the close relationship of these 2 VP4 subtypes as measured by crossneutralization.
DISCUSSION
Previously, antigenic relationships among the VP4 outer capsid proteins of various rotaviruses were studied using VP4 neutralizing monoclonal antibodies or antisera to reassortant rotaviruses (14, 16, 17) . More recently, the neutralizing antibody response to VP4 was studied using the VP4 recombinant protein of porcine strain OSU (9) and simian strain RRV (18) . Those studies indicated that it was possible to distinguish between the VP4 of OSU or RRV as well as the VP4 of other animal and human strains by neutralization assay.
To gain a more detailed understanding of the VP4 antigenic relationships among HRVs, antibodies were induced against the baculovirus recombinant-expressed VP4 protein of human rotavirus strain KU, DS-1, or 1076. The VP4 of these strains represents three of the four distinct alleles identified thus far among HRVs (4-7). Nucleotide sequence analysis indicated that the VP4 genes of strain KU (genetic group 1) and strain DS-1 (genetic group 2) were more closely related to each other than to the VP4 of strain 1076 (genetic group 3). Also, it was observed that the VP4 of K8 virus, the prototype strain of genetic group 4, was the most divergent of the four distinct groups. A direct correlation was observed between VP4 amino acid homology and antigenic relatedness as measured by neutralization. For level of cross-reactivity by immunoprecipitation and neutralization. This is consistent with prior monoclonal antibody analysis, which suggested that neutralization specificity is mainly determined by the VP8 subunit (14) . Strains ofgenetic groups 3 and 4, which were poorly neutralized by antisera to expressed VP4 protein of strain KU or DS-1, probably have relatively few epitopes in the VP8 subunit that are shared by genetic groups 1 and 2. On the other hand, the VP8 epitopes shared by strains of group 1 and group 2 are probably responsible for their high level of cross-reactivity observed in neutralization tests.
Recent studies indicate that antibodies induced by immunization with VP8 may be used in an ELISA to determine the VP4 serotype of rotavirus isolates. In addition, expressed VP8 subunit may be used to measure VP4 serotype-specific antibodies in sera of animals and humans obtained following rotavirus infection. This type of information should prove helpful in devising more effective strategies for prevention of serious rotavirus disease by immunization. The immunogenicity of the VP4 component of various immunogens, live or inactivated, can now be assayed directly. In addition, since antiserum to the VP4 of KU, the prime strain ofVP4 serotype 1, was capable of neutralizing to high-titer viruses belonging to each of the four epidemiologically important human VP7 serotypes, it may be possible to induce immunity in infants to a broad range of HRVs using a vaccine containing a single attenuated rotavirus strain possessing a serotype 1A VP4.
